Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 2/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.30 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.30 |
| ▸ | CCKBR | P32239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21728997 | 0.97 | FOLH1 (0.31) | BMP1 | |
| SCHEMBL21738718 | 0.84 | GPBAR1 (0.31) | — | |
| SCHEMBL27104562 | 0.83 | KDM4E (0.37) | — | |
| SCHEMBL20224390 | 0.83 | KDM4E (0.37) | — | |
| SCHEMBL27104564 | 0.81 | KDM4E (0.37) | — | |
| SCHEMBL25767688 | 0.80 | FOLH1 (0.41) | BMP1ADAMTS4ADAMTS5CCKBR | |
| SCHEMBL12010939 | 0.80 | MMP2 (0.39) | BMP1ADAMTS4ADAMTS5CCKBR | |
| SCHEMBL18897776 | 0.78 | BMP1 (0.36) | BMP1 | |
| SCHEMBL26353660 | 0.77 | GPBAR1 (0.35) | BMP1 | |
| SCHEMBL23802494 | 0.77 | DPP4 (0.39) | BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308267-A1 | REJUVENATION OF CAR T CELL | PURDUE RESEARCH FOUNDATION | 2021-10-07 | — | — | US | disclosed |
| US-20200054676-A1 | Targeted Ligand-Payload Based Drug Delivery for Cell Therapy | PURDUE RESEARCH FOUNDATION | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308267-A1 | REJUVENATION OF CAR T CELL | HAVCR2, ICOS, CD47 | BMP1 2256/4885ADAMTS4 2444/4885ADAMTS5 2797/4885 |
| US-20200054676-A1 | Targeted Ligand-Payload Based Drug Delivery for Cell Therapy | HAVCR2, BST2, CD74 | BMP1 558/4885ADAMTS4 3150/4885ADAMTS5 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.